Spectrum Health Advanced Technology Laboratories are proud to announce that the first and only FDA-approved blood test for colorectal cancer screening is now available at Spectrum Health Molecular Diagnostics Laboratory. The Epi proColon Septin 9 Methylation Analysis test is indicated to screen adults of either sex, 50 years or older, defined as average risk for colorectal cancer (CRC), who have been offered and have a history of not completing CRC screening.
Effective September 23, 2016, Spectrum Health Regional Laboratory Molecular Diagnostics Department is pleased to announce that the HIV-1 Quantitative RNA PCR (Test Code #7125) has been added to our in-house test menu.
Spectrum Health Regional Laboratory (SHRL) was featured on Medical Moment on Fox 17 News, Monday, September 19, 2016. Watch the clip below to go behind the scenes of our Advanced Technology Laboratories with Kim Collison, Director of Laboratory Services. Learn how ATL provides rapid turn-around of unique testing performed right here in West Michigan, which supports many key services such as oncology.
For more information on the testing that SHRL and ATL offer, please visit our Laboratory Catalog.
Spectrum Health Regional Laboratory (SHRL) was featured on EightWest on WOOD TV8 on Tuesday, August 30, 2016. Dr. Stephanie F. Williams, Division Chief of Spectrum Health Adult Bone and Marrow Transplant, and Kim Collison, Director of Laboratory Services, talk about the importance and benefits of having SHRL’s Advanced Technology Laboratory right here in West Michigan.
The Advanced Technology Laboratory is “extremely important, particularly for patients with certain cancers…”
“It helps us to diagnose the patients faster and more accurately; to follow the progress of their disease during the treatments that we give, and even at times to guide us in what is the best treatment for a patient…”
“Within 2 hours we had the answer. We did not have to send that specimen out to another laboratory in another state.”
-Stephanie F. Williams, MD, Division Chief, Spectrum Health Adult Bone and Marrow Transplant
Effective June 6, 2016, Spectrum Health Regional Laboratory Molecular Diagnostics Department is pleased to announce the addition of the MPN Expanded Panel (Test #7090, Epic #LAB3611).
The treatment of non-small cell lung adenocarcinoma has become more successful due to targeted treatments based on the molecular profile of a patient’s particular tumor. The Lung Cancer Mutation Analysis panel is now available for clinical testing at the Spectrum Health Advanced Technology Laboratories (ATL).
The Spectrum Health Laboratory is now reporting all Hepatitis C Antibody results as Negative or Positive only. (Hepatitis C Antibody, Screening; Hepatitis C Antibody, Diagnostic) The separate Low Positive result category has been eliminated.
The Laboratory has changed to a new Hepatitis C Antibody reagent which no longer includes the Low Positive result category in its product labeling (the FDA approved instructions which laboratories are required to follow). The Low Positive category was defined on the basis of old guidelines which indicated that results above a defined S/CO (signal/cutoff) value were considered to have a 95% or greater probability of being true positives and did not require RIBA confirmation. The RIBA confirmatory test has not been available for several years now. Current guidelines are that all positive Hepatitis C Antibody tests should be confirmed with a HCV RNA test. The Spectrum Health laboratory reflexes all positive antibody results to this test. A positive HCV RNA following a positive antibody result should be considered indicative of active HCV infection, and may be used as a baseline for antiviral therapy.
Any questions concerning this change in Hepatitis C Antibody reporting may be directed to Dr. Richard Horvitz in the Pathology department.
Spectrum Health Information Services has added an Ask at Order Entry question (AOE) “Has signed informed consent been obtained from the patient: Yes/No” to these tests. If the answer to this question is no, testing will either not be drawn (outpatient) or cancelled until informed consent is obtained by the ordering provider. Link to Informed Consent Form.
Tests which require informed consent:
|A1AT Proteotype S/Z||FISH for Trisomy 21|
|Alpha Globin Gene Analysis||FISH for Turner|
|Alpha1AT Defic Profile||FISH for Williams|
|Angelman/Prader Willi (15q11-q13) by FISH||FISH for Wolf-hirschhorn|
|Angelman/Prader Willi mPCR||FISH for XX and XY|
|CF Carrier Screening by Sequenom||FISHAneuTCPanel|
|CF Gene Sequencing to MAYO||FISHDiGeorge|
|Chromosomal Microarray (CGH)||FISHDownSyn|
|Chromosome Analysis Constitutional||FISHMillerDieke|
|Chromosome Analysis POC||FISHPraderWilli|
|Chromosome Analysis Prenatal||FISHSmithMageni|
|Factor V Leiden DNA Analysis||FISHSubtelomeres|
|FISH for aneuVysion||FISHWilliams|
|FISH for Common trisomies in POC||FISHWolf|
|FISH for DiGeorge||FISHXXYYSRY|
|FISH for Down syndrome||Hemochromatosis DNA|
|FISH for Major trisomies||Huntington’s Disease Molecular Analysis|
|FISH for Miller-dieker||MTHFR C677T|
|FISH for Prader-willi||Prothrombin G20210A|
|FISH for Smith-Magenis||Send Out CMA|
|FISH for Subtelomeres|